
Avis Budget Group, Inc.
CAR
Updated: 24/09/2026, 14:10:13
Avis Budget Group, Inc. is a prominent global provider of diverse mobility solutions, delivering vehicle rental services for both cars and trucks, alongside car-sharing options, to a broad clientele encompassing businesses and individual consumers. The company's brand portfolio includes Avis, which focuses on providing premium vehicle rentals and comprehensive mobility solutions to both commercial and leisure segments of the travel industry. For truck and cargo van rentals, the Budget Truck brand operates a fleet of approximately 20,000 vehicles. These are available for local and one-way hire through a vast network of roughly 465 dealer-operated and 385 company-owned locations across the continental United States, catering to both residential and light commercial needs. Furthermore, the company manages Zipcar, a well-known car-sharing network, and an array of other car rental brands such as Budget, Payless, Apex, Maggiore, MoriniRent, FranceCars, Amicoblue, Turiscar, and ACL Hire. Beyond its core vehicle offerings, Avis Budget Group supplies an extensive range of supplementary products and services. These include various optional insurance covers, such as supplemental liability, personal accident, personal effects protection, emergency sickness, and insurance for automobile towing and cargo. Customers can also access fuel service plans, roadside assistance, electronic toll collection, curbside delivery, and rentals for items like tablets, satellite radio access, portable navigation units, and child safety seats. For moving purposes, the company provides automobile towing equipment and essential accessories such as hand trucks, furniture pads, and moving supplies. Additionally, corporate clients benefit from a Business Intelligence solution, an online platform designed for managing their corporate travel needs. With a significant international presence, Avis Budget Group, Inc. operates at approximately 10,400 locations across the globe. Founded in 1946 and headquartered in Parsippany, New Jersey, the company was formerly named Cendant Corporation before adopting its current name in September 2006.
No summaries found.
- Share price
- $105.67
- Market cap
- $3.73B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Brian J. Choi
- Employees
- 21,000
- IPO date
- 14/09/1983
- Beta
- 1.902
- Last dividend
- $0.00
- Day range
- $104.95 – $110.75
- 52-week range
- $85.96 – $847.70
- 1-day performance
- -1.91%
- 1-year performance
- 22.93%
- Current drawdown (1Y)
- -87.53%
- CIK
- 0000723612
- CUSIP
- 053774105
- ISIN
- US0537741052
- Created
- 07/12/2025, 03:11:23
- Last update
- 24/09/2026, 14:10:13
Track Avis Budget Group, Inc. with an AI analyst
See which prediction-market events move CAR, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
GlobeNewsWire • STOCK • 15/06/2026, 10:00:00
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
GlobeNewsWire • STOCK • 14/06/2026, 05:15:00
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection
Seeking Alpha • STOCK • 13/06/2026, 14:23:38
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
GlobeNewsWire • STOCK • 09/06/2026, 09:00:00
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
MarketBeat • STOCK • 09/06/2026, 08:06:02
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
Accesswire • STOCK • 04/06/2026, 10:40:00
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
GlobeNewsWire • STOCK • 02/06/2026, 11:30:00
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
PRNewsWire • STOCK • 01/06/2026, 09:00:00
CAR's Strategic Mobility Partnerships Offer Long-Term Opportunities
Zacks Investment Research • STOCK • 28/05/2026, 16:55:35
Avis Budget Group Announces Pricing of $300 Million of Senior Notes
GlobeNewsWire • STOCK • 27/05/2026, 19:21:00
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen
GlobeNewsWire • STOCK • 27/05/2026, 09:45:00
Avis Budget Group Announces Intention to Offer $300 Million of Senior Notes
GlobeNewsWire • STOCK • 27/05/2026, 09:30:00